TRA-1-60 Antibody (TRA-1-60): sc-21705

TRA-1-60 Antibody (TRA-1-60) is a mouse monoclonal IgM kappa light chain antibody that specifically detects the TRA-1-60 antigen, a carbohydrate epitope present on podocalyxin-like protein 1 (PODXL), also known as sialomucin protein, CD34 family member, glomerular podocyte cell surface marker, or hematopoietic stem cell surface antigen. PODXL is a heavily glycosylated transmembrane protein that plays a critical role in maintaining cell morphology and promoting cell migration due to its anti-adhesive properties. PODXL is prominently expressed on the surface of undifferentiated human embryonic stem cells and embryonal carcinoma cells, making PODXL an important marker for pluripotency and stem cell research. The TRA-1-60 antigen, which is neuraminidase-resistant and represents a sialylated epitope on podocalyxin, is associated with the surface of embryonal carcinoma (EC) cells, the stem cells of teratocarcinomas, and is coexpressed with other stem cell markers such as TRA-1-81 and Stage-Specific Embryonic Antigens (SSEA-3 and SSEA-4). TRA-1-60 expression is lost upon stem cell differentiation, making anti-TRA-1-60 antibody (TRA-1-60) an essential marker for identifying and isolating undifferentiated cells. TRA-1-60 (TRA-1-60) monoclonal antibody is particularly valuable for applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM), enabling researchers to monitor stem cell pluripotency and differentiation status, critical aspects of regenerative medicine and developmental biology studies. Additionally, PODXL expression, associated with tumor progression and metastasis in certain cancers, further highlights anti-TRA-1-60 antibody (TRA-1-60) significance. Notably, TRA-1-60 can also be detected in the serum of patients with germ cell tumors containing an embryonal carcinoma component, underscoring TRA-1-60 (TRA-1-60) antibody utility in both cancer research and diagnostics.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

TRA-1-60 Antibody (TRA-1-60) References:

1. The human embryonal carcinoma marker antigen TRA-1-60 is a sialylated keratan sulfate proteoglycan.  |  Badcock, G., et al. 1999. Cancer Res. 59: 4715-9. PMID: 10493530
2. TRA-1-60: a new serum marker in patients with germ-cell tumors.  |  Marrink, J., et al. 1991. Int J Cancer. 49: 368-72. PMID: 1717384
3. Human embryonal carcinoma cells and their differentiation in culture.  |  Andrews, PW., et al. 1987. Int J Androl. 10: 95-104. PMID: 2438234
4. The Universal 3D3 Antibody of Human PODXL Is Pluripotent Cytotoxic, and Identifies a Residual Population After Extended Differentiation of Pluripotent Stem Cells.  |  Kang, L., et al. 2016. Stem Cells Dev. 25: 556-68. PMID: 26886504
5. First identification of PODXL nonsense mutations in autosomal dominant focal segmental glomerulosclerosis.  |  Lin, FJ., et al. 2019. Clin Sci (Lond). 133: 9-21. PMID: 30523047
6. Upregulation of PODXL and ITGB1 in pancreatic cancer tissues preoperatively obtained by EUS-FNAB correlates with unfavorable prognosis of postoperative pancreatic cancer patients.  |  Taniuchi, K., et al. 2022. PLoS One. 17: e0265172. PMID: 35275973
7. Selective ablation of TRA-1-60+ pluripotent stem cells suppresses tumor growth of prostate cancer.  |  White, JM., et al. 2023. Theranostics. 13: 2057-2071. PMID: 37153742
8. Isolation of a primate embryonic stem cell line.  |  Thomson, JA., et al. 1995. Proc Natl Acad Sci U S A. 92: 7844-8. PMID: 7544005
9. Retinoic acid-induced differentiation of the developmentally pluripotent human germ cell tumor-derived cell line, NCCIT.  |  Damjanov, I., et al. 1993. Lab Invest. 68: 220-32. PMID: 7680083
10. Comparative analysis of cell surface antigens expressed by cell lines derived from human germ cell tumours.  |  Andrews, PW., et al. 1996. Int J Cancer. 66: 806-16. PMID: 8647654
11. Pluripotent cell lines derived from common marmoset (Callithrix jacchus) blastocysts.  |  Thomson, JA., et al. 1996. Biol Reprod. 55: 254-9. PMID: 8828827
12. Importance of a new tumor marker TRA-1-60 in the follow-up of patients with clinical stage I nonseminomatous testicular germ cell tumors.  |  Gels, ME., et al. 1997. Ann Surg Oncol. 4: 321-7. PMID: 9181232

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-TRA-1-60 Antibody (TRA-1-60) has 206 citations in a variety of scientific publications.

Primary antibodies like Anti-TRA-1-60 Antibody (TRA-1-60) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

TRA-1-60 Antibody (TRA-1-60) Specifications

Alternate Product Name: Podocalyxin

Product Clone Name: TRA-1-60

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgM kappa light chain

Amino Acids:

Epitope Target: TRA-1-60

Epitope Species: human

Product Reactivity/Detection: TRA-1-60

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, FCM

Vialing Information: Each vial contains 200 µg IgM kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 206 citations in various scientific publications

Available Conjugates/Forms for TRA-1-60 Antibody (TRA-1-60): N/A